FDA
-
Malvern Gene Company to Raise $115M from Convertible Notes While Dealing with Stock Decline
Malvern-based Ocugen saw its stock fall almost 20 percent after an announcement to use convertible notes to pay down existing debt and fund ongoing drug…
-
Three Philadelphia Scientists Win 2026 Breakthrough Prize for FDA-Approved Gene Therapy Development
Three Philadelphia scientists were recently named the winners of the 2026 Breakthrough Prize for their work in developing the first FDA-approved gene therapy for a…
-
Plymouth Meeting Pharmaceutical Company Eyes $1B Milestone
Harmony Biosciences says its flagship narcolepsy drug is on track to hit a major milestone, writes John George for The Philadelphia Business Journal. The Plymouth…
-
As Food Dye Reckoning Nears, Horsham’s Bimbo Bakeries is Ahead of the Curve
As new food regulations begin reshaping the U.S. grocery aisle, Horsham-based Bimbo Bakeries USA is emerging as an industry leader in eliminating artificial dyes, writes…
-
First-in-Human Study of DNA Antibody Replicas Generate Efficient and Long-Lasting Biologic Production of Human Antiviral Antibodies
A multidisciplinary team of scientists led by The Wistar Institute, including Perelman School of Medicine at the University of Pennsylvania, AstraZeneca and Inovio Pharmaceuticals, published in Nature Medicine a breakthrough…
-
Merck Finalizes $10 Billion Acquisition, Expands COPD Treatment Portfolio
Pharmaceutical giant Merck, which maintains major operations in Montgomery County, has completed its $10 billion acquisition of Verona Pharma, writes the New Jersey Business and…
-
Conshohocken’s ActiveProtective Launches Tango Belt, Eyes Nationwide Expansion
Conshohocken-based ActiveProtective has launched the Tango Belt, a fall prevention device that has been approved by the Food and Drug Administration, writes John George for…
-
WSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration Nears
Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall Street Journal. The…
-
Malvern Biotechnology Company Develops New Blood Test to Diagnose Alzheimer’s
Malvern biotechnology company Fujirebio Diagnostics has developed a revolutionary new test to diagnose Alzheimer’s disease, writes Harold Brubaker for The Philadelphia Inquirer. Previously, FDA-approved Alzheimer’s…
-
Synthetic Dye Ban Puts Philadelphia’s Classic Treats at Risk
With the Department of Health and Human Services, led by Robert F. Kennedy Jr., moving to phase out eight petroleum-based artificial food dyes, several iconic…
-
WSJ: Penn Hospital Doctors Perform Revolutionary Procedure Involving Brain-Computer Implant
Doctors at Pennsylvania Hospital in Philadelphia recently performed a revolutionary procedure by temporarily implanting a brain-computer interface device onto a patient’s brain, writes Jo Craven…
-
Center City-based Digital Pathology Tech Company Proscia Receives FDA Approval To Expand Marketing Efforts
Proscia Inc., a Center City-based digital pathology services company, has received a crucial Food and Drug Administration approval, writes John George for the Philadelphia Business…
-
Wall Street Journal: University City-based BioTech Firm Nears Human Trials for Breakthrough Artificial Womb Technology
University City-based Vitara Biomedical is currently working on an artificial womb for premature babies and is getting closer to human clinical trials, writes Liz Essley…
Founding Partners
Advertisement
Affiliate Partners
